The global phase 3 trial enrolled 309 patients with grade 1 or 2 progressive somatostatin receptor (SSTR)-positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Clinicopathological factors related to survival in gastroenteropancreatic neuroendocrine tumors (GEP-NET): 20 years experience in the American British Cowdray Medical Center. This is an ASCO Meeting ...

The study evaluated the use of RLT earlier as a first-line (or “up front”) treatment for patients newly diagnosed with grade 2 or 3 advanced gastrointestinal neuroendocrine tumours. Although ...

The study evaluated the use of RLT earlier as a first-line (or "up front") treatment for patients newly diagnosed with grade 2 or 3 advanced gastrointestinal neuroendocrine tumors. Although ...

The study evaluated the use of RLT earlier as a first-line (or “up front”) treatment for patients newly diagnosed with grade 2 or 3 advanced gastrointestinal neuroendocrine tumours. Although ...

slashed the risk of disease progression or death by 72% versus high-dose octreotide LAR alone in newly diagnosed patients with grade 2 or 3 advanced gastroenteropancreatic neuroendocrine tumors ...

improves progression-free survival outcomes for patients with grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET). Lutathera is a type of radioactive drug that treats ...

They are high grade. All large bowel and rectal neuroendocrine carcinomas (NECs) are grade 3. There are 2 main types of neuroendocrine cancer in the large bowel and rectum: large bowel and rectal ...

Risk of myelodysplastic syndrome/acute leukemia with sequential capecitabine/temozolomide and 177Lu-dotatate. This is an ASCO Meeting Abstract from the 2022 ASCO ...